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Abstract
Positive and negative selection in the thymus relies on T-cell receptor recognition of 
peptides presented by HLA molecules and determines the repertoire of T cells. Immune 
competent T-lymphocytes target cells display nonself or pathogenic peptides in complex 
with their cognate HLA molecule. A peptide passes several selection processes before 
being presented in the peptide binding groove of an HLA molecule; here the sequence 
of the HLA molecule’s heavy chain determines the mode of peptide recruitment. During 
inflammatory processes, the presentable peptide repertoire is obviously altered com-
pared to the healthy state, while the peptide loading pathway undergoes modifications 
as well. The presented peptides dictate the fate of the HLA expressing cell through their 
(1) sequence, (2) topology, (3) origin (self/nonself). Therefore, the knowledge about pep-
tide competition and presentation in the context of alloreactivity, infection or pathogenic 
invasion is of enormous significance. Since in adoptive cellular therapies transferred cells 
should exclusively target peptide-HLA complexes they are primed for, one of the most 
crucial questions remains at what stage of viral infection viral peptides are presented 
preferentially over self-peptides. The systematic analyzation of peptide profiles under 
healthy or pathogenic conditions is the key to immunological success in terms of person-
alized therapeutics.
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1. Introduction
The immune system of all species has to be able to discriminate self and foreign (nonself) 
antigens to combat infections without eliciting autoimmune diseases. The presentation of self 
and nonself occurs through displaying cellular proteins on the cell surface by proteins of the 
major histocompatibility complex (MHC) gene cluster. In humans, the MHC locus is termed 
human leukocyte antigen (HLA) and comprises several gene loci with numerous different 
alleles for most of the genes [1]. One part of the genes is subsumed as HLA class I (HLA-I) 
with the gene products being expressed on virtually every nucleated cell in the human body. 
HLA-I molecules present peptides of intracellular proteins on the cell surface. Cytotoxic T 
cells (CD8+ T cells) as part of the adaptive immune system can recognize these peptide HLA-I 
(pHLA-I) complexes by the T-cell receptor (TCR) and scan simultaneously the HLA molecule 
and the peptide [2, 3] to discriminate between healthy and unhealthy cells, for example, virally 
infected cells. At the same time, natural killer (NK) cells that are part of the innate immune 
system scan the cell surface of HLA as well. These cells become activated when HLA-I is miss-
ing on the cell surface, for example, on virally infected or tumor cells [4].
Peptide loading on HLA-I is a complex mechanism and determines in addition to the HLA 
allele which peptides will be presented. The central part of this process is the peptide loading 
complex that is localized in the endoplasmic reticulum (ER). The HLA-I molecule, consisting 
of a heavy chain and a microglobulin, is stabilized by several chaperons since the structure 
is unstable when no peptide is bound. The transporter associated with antigen processing 
(TAP) imports protein fragments that are degraded in the cytosol by the proteasome into the 
ER. Depending on the sequence, these peptides are trimmed in different ways in the ER [5, 6]. 
The bridge between TAP and HLA-I is the chaperon tapasin (TPN) that facilitates peptide bind-
ing in the peptide binding groove [7].
Because the HLA gene cluster ranks among the most polymorphic region in the human 
genome [1] and most of these polymorphisms are located in the peptide binding region 
(PBR) [8, 9], these polymorphisms result in an abundance of structurally different pHLA enti-
ties. In this chapter, we focus on the interplay between HLA alleles, bound peptides and 
the interaction with immune receptors. It is highlighted that even minor differences in the 
HLA sequence can impact on the bound ligand or the pHLA structure. Every single peptide 
changes the overall structure of the HLA molecule. Structural alterations that differ from self-
pHLA structures will be recognized by the immune system. Therefore, the last parts of the 
chapter demonstrate the advantage of established immunopeptidomes for immunotherapies.
2. Peptide selection and presentation
The viability of the immune system is governed by interactions between effector cell receptors 
and their cognate antigenic ligands. Immune effector cells survey HLA-I molecules on the sur-
face of antigen-presenting cells by indirectly scanning the proteomic content of every single 
cell. The fundamental role of CD8+ T cells, the elimination of pathogens, is elicited through 
HLA-I molecules complexed to a peptide of foreign (e.g., viral) origin.
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Positive and negative selection of T cells in the thymus is a critical step for the development of 
a mature functional immune system. Immune cells that have not developed immune tolerance 
against specific pHLA-I complexes during thymus selection will recognize these antigens as 
foreign. The allele-specific and patient-specific peptides that are presented on the cell sur-
face shape the individual immune response. Even a single alteration in the peptide sequence 
can be recognized by immune effectors. Single alterations in the sequence of the HLA heavy 
chain might not affect which peptide sequences can be bound but could lead to a modified 
overall pHLA-I structure or might affect the strength of peptide binding resulting in pHLA-I 
complexes with different half-life times. Besides the influence of amino acid (AA) exchanges 
within the heavy chain, peptides might undergo competition in patients who carry alleles 
with the same peptide-binding motif. For those reasons, the presentation of a given peptide 
is dependent on the HLA type and the health status of the patient. Half-life times of pHLA 
Figure 1. Viral interference with HLA class I peptide presentation. Depicted are targets for viral interference with peptide 
presentation on HLA-I molecules. HLA-I maturation and surface presentation of peptides are blocked through different 
mechanisms early postinfection. Most viruses directly target peptide loading through TAP and peptide optimization 
by tapasin (HCMV [104, 105], HSV [106], HPV [107], ADV [108], EBV [109]). Additionally, cell surface expression is 
impeded by retention of HLA-I in the ER (ADV [110], HIV [111], HCMV [112]) or rapid degradation of surface molecules 
(HHV-8 [113], HIV [114]). Other possibilities include dislocation of the HLA-I heavy chain before any peptide loading 
can occur (HCMV [115, 116]) and inhibition of proteasomal processing of viral proteins by the host cell (EBV, HCMV 
[117, 118]).
Peptide Presentation Is the Key to Immunotherapeutical Success
http://dx.doi.org/10.5772/intechopen.76871
7
complexes influence the phenotype and/or functionality of T cells. That has to be taken into 
account when choosing pHLA-I targets for T-cell therapeutics. Based on these facts the impor-
tance of knowledge about allelic peptide specificity becomes obvious. Peptides have to pass 
several intracellular filters and processing steps before being presented to immune effectors 
cells. The bottleneck is the peptide loading complex (PLC). Not every available peptide in a 
cell would be necessarily bound to an HLA molecule and displayed at the cell surface since 
peptides undergo peptide competition during recruitment through the PLC. The PLC con-
sists of several proteins; each has a specialized function for peptide selectivity and specificity. 
Proteins of this complex are dedicated targets for viral interference and thus viral immune 
evasion (Figure 1).
The HLA heavy chain has to adopt a peptide-receptive form and complex with certain pro-
teins of the PLC. It could be demonstrated that certain allelic variants interact differently 
with proteins of the PLC and thus are more prone to present peptides of malignant origin. 
Those HLA subtypes can differ from alleles that are strictly dependent on the association 
with the PLC for peptide loading only by a single amino acid within the heavy chain, alter-
ing the structural interface that interacts with the PLC [10–12]. Especially the interaction of 
TPN, a protein that mediates the binding of high-affinity peptides into the HLA-I PBR, with 
the HLA-I molecule, is of exquisite importance to produce stable pHLA-I complexes that 
persist on the cell surface. However, few allelic HLA variants are able to present peptides 
without the assistance of TPN. That enables those alleles to continuously present viral pep-
tides at an infectious stage where viral interference with TPN occurs; however, the presenta-
tion of self-peptides that did not take part in negative T-cell selection would be facilitated 
and might lead to uncontrollable autoimmune reactions. HLA-I variants that select and load 
peptides without the assistance of TPN are likely to present a broad range of low-affinity 
viral-derived peptides during an infection. However, the presentation of viral peptides dur-
ing an active viral infection is a rare event since still self-peptides are present intracellularly 
and would compete with viral peptides to fit into the PBR. The viral peptides that would 
reach the cell surface complexed to an HLA-I molecule could hardly be predicted by peptide 
prediction tools.
3. Peptide specificity
Due to the fact that peptides undergo different selection steps before being presented by an 
individual HLA allele, it has to become clear that the individual HLA profile is the major and 
most distinguished obstacle. Every HLA allele differs from another by the composition of 
AAs in and/or outside the peptide-binding groove, resulting in allele-specific profiles of the 
bound peptides [13–15]. Therefore, the knowledge of an individual peptide binding profile 
can be used as precedence for the measurement of permissivity between HLA subtypes. The 
sequence, length and immunogenicity of a given peptide determine the half-life time of the 
whole pHLA complex and furthermore the specificity and reactivity of their cognate immune 
receptor.
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Several studies demonstrated the impact of the sequence and feature of HLA-bound pep-
tides on receptor recognition. This observation holds true for T-cell receptors of the adap-
tive immune system as well as for NK-cell receptors of the innate immune system. We 
recently could highlight the potential of the nonclassical HLA-I molecule HLA-E to select 
and present peptides of extraordinary length and their effect on differential NK-cell recog-
nition. For the nonpolymorphic HLA-E molecule only two functional variants exist distin-
guished by a single AA difference. That would imply that HLA-E is, in regard to its peptide 
profile, invariant. However, by sequencing their bound ligands, we found both alleles pre-
senting a different set of peptides [16]. Since HLA-E is an intermediate molecule for the 
adaptive and innate immune system, supporting the non-PLC-dependent presentation of 
peptides during HLA downregulation episodes, the invariability of this molecule would 
certainly make biological sense. However, the finding that HLA-E subtypes differ in their 
immunity was somehow unexpected. Reconstitution of empty HLA-E molecules with the 
designated peptides on the surface of artificial APCs resulted in a peptide-specific immune 
recognition [17].
Two types of NK-cell receptors interact with HLA-I molecules, killer cell immunoglobulin-
like receptors (KIRs) and C-type lectin-like receptors. The former ones are highly polymor-
phic and polygenic in the population and recognize HLA-A, -B and -C alleles [18], whereas 
the latter ones bind among others to HLA-E [19, 20]. CD8+ T cells recognize endogenous HLA 
alleles and assess their immune status by virtue of the presented peptide. The display of dif-
ferent peptides thus allows for precise monitoring of the immune status of the cell through 
the adaptive immune system. However, this also means that these cells have to be primed on 
the recognition of specific peptides that are usually derived from endogenously expressed 
proteins [21]. The presented peptide repertoire can be altered by aberrant protein expression 
as well as the presence of foreign proteins (e.g., viral proteins) in the cell. To counter recogni-
tion by CD8+ T cells, many viruses have developed immune evasion strategies that specifically 
target HLA peptide loading and presentation. For instance, the HCMV protein US6 interferes 
with peptide translocation at the ER thus depriving the available peptide pool or even directly 
procures that the HLA heavy chain is degraded through US2 or US11 [22]. However, in the 
event of such disrupted HLA-I presentation, NK cells become activated. Although NK cells 
do not recognize the specific HLA allele, the absence of HLA expression on the cell surface 
triggers NK-cell activation. Nevertheless, NK cells can still recognize certain peptides in the 
context of the nonclassical HLA molecule HLA-E that presents a very narrow set of peptides 
derived from the signal sequence of other HLA class I molecules. These peptides are 9 AA 
in length and are anchored preferably by Met at peptide position p2 and Leu at pΩ, whereas 
positions p4, p5 and p6 are accessible to the solvent [23, 24]. On NK cells, HLA-E in com-
bination with these peptides is recognized by inactivating the NKG2A/CD94 heterodimeric 
receptor complex [25]. In the absence of HLA class I molecules or during cell stress, HLA-E 
was shown to present noncanonical peptides of different length [16, 17], for example, the 
Hsp60-derived peptide QMRPVSRVL that causes loss of recognition by NKG2A/CD94 [26] 
or the HIV Gag-derived peptide AISPRTLNA that causes HLA-E upregulation [27]. In the 
case of HCMV, a peptide from the UL40 protein that closely resembles the sequence of leader 
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peptides from certain HLA-C allotypes is provided to stabilize HLA-E expression in infected 
cells. However, in individuals negative for these HLA-C allotypes, the UL40-peptide consti-
tutes the presentation of nonself on HLA-E and can thus elicit a CD8+ T-cell response [19, 28]. 
Additionally, HLA-E in complex with other pathogen-derived peptides was shown to stimu-
late CD8+ T-cell responses. For instance, the Epstein–Barr virus-derived peptide SQAPLPCVL 
was shown to be recognized by the αβTCR of a CD8+-CD94/NKG2C+ T-cell clone [29, 30] 
described HLA-E-restricted Salmonella enterica serovar Typhi-specific CD3+CD8+CD4−CD56− T 
cells. These diverse interactions demonstrate the subtle interaction of innate and adaptive 
immunity through the presented peptide on HLA-E.
4. Peptide binding prediction, bioinformatic tools
To identify peptides that would be suitable for application in cellular therapeutic strate-
gies, certain properties have to be analyzed: (1) the peptide-binding motif of the HLA 
allele of choice and (2) the HLA allele-specific features of the bound peptides such as 
length and topology. There are several bioinformatic tools that enable scientists and cli-
nicians to predict peptides that would be presented by a certain HLA allele, yet, these 
tools do not consider allele-specific features and immune dominance of peptides. The 
kinetics of antigen expression and the competition of peptides to be preferentially bound 
and presented are also not considered by these bioinformatics prediction tools. Most 
data available in these tools are based on experimental peptide data (Tables 1 and 2). 
However, it remains unclear if those predicted peptides would ever be naturally pre-
sented. Peptides predicted from for example a viral protein would not necessarily be 
processed, selected and/or presented by the respective patient awaiting T-cell therapy. 
Therefore, the pathogen- or peptide-specific T cells that would be transplanted might 
not be able to find their mutual pHLA molecule. An example of the first successful adop-
tive transfer of virus-specific T cells described the transfer of HCMV-specific T cells and 
their reconstitution of antiviral immunity in an immune-deficient bone marrow trans-
plant recipient [31]. The technique of adoptive T-cell transfer could be further improved 
leading to the selection of specific T-cells based on IFN-γ secretion or pHLA multimer 
staining and selection following antigen stimulation [32–34]. Both techniques bear the 
imperative to know which viral peptides are presented on the particular HLA subtype 
of, for example, HCMV-infected cells. So far, few HLA-restricted peptides have been 
studied. The majority of peptides are derived from the well-characterized phospho-
protein (pp)65 or the immediately early (IE)1 protein, however, not for every patient 
responses against these two proteins are immunodominant [35, 36]. Best studied are the 
pp65-derived peptides NLVPMVATV and TPRVTGGGAM, restricted to HLA-A*02:01 
and HLA-B*07:02, respectively. Those peptides are described to induce extremely strong 
T-cell responses [37–42]. Yet, these peptides have been computationally predicted [43] 
but not been isolated from HLA molecules. Thus, it remains unproven if they would ever 
be naturally presented. That might be an explanation for the failure of long-term T-cell 
transfers [33, 44, 45].
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Name Application Methods Ref. Number of 
HLA class I 
alleles
Number of 
HLA class II 
alleles
Peptide 
length
Other species URL
BIMAS Predicts half-time of 
dissociation of peptides 
from protein sequences
Coefficient 
tables
[58] 41 inc. 
supertypes
0 8–10 No https://www-bimas.cit.
nih.gov/molbio/hla_bind/
EpiJen Predicts peptide binding 
from protein sequence 
(proteasome cleavage, TAP 
binding and MHC binding)
Multi-step 
algorithm
[59] 18 0 9 No http://www.ddg-
pharmfac.net/epijen/
EpiJen/EpiJen.htm
hla_a2_smm Predicts binding affinity 
of peptides, high affinity 
HLA-A2 binding peptides 
from protein sequence and 
mutated peptides with 
higher affinity
SMM pair 
coefficients
[60] 1 0 9–10 No https://zlab.bu.edu/SMM/
IEDB T Cell 
Epitope 
Prediction Tools
Predicts T cell epitopes 
from proteins (MHC 
binding, processing and 
immunogenicity)
Several tools 
can be chosen
[61–64] 77 n/s Class I:8–14
Class II: n/s
Chimpanzee, 
cow, gorilla, 
macaque, mouse, 
pig, rat for MHC 
class I; mouse for 
MCH class II
http://tools.iedb.org/
main/tcell/
Mappp Predicts antigenic peptides 
to be processed and 
presented by MHC class 
I from peptide or protein 
sequence
Uses BIMAS 
or SYFPEITHI 
for binding 
prediction
[65] 35 inc. 
supertypes
0 8–10 Mouse, cattle http://www.mpiib-berlin.
mpg.de/MAPPP/index.
html
http://www.mpiib-berlin.
mpg.de/MAPPP/binding.
html
MHC2MIL Predicts binding affinity 
of MHC-II peptides from 
protein sequence
MIL [66] 0 26 9–25 No http://datamining-iip.
fudan.edu.cn/service/
MHC2MIL/index.html
MHC2PRED Prediction of MHC class II 
binders
SVM [67] 0 38 inc. 
supertypes
9 Mouse http://crdd.osdd.net/
raghava/mhc2pred/
index.html
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Name Application Methods Ref. Number of 
HLA class I 
alleles
Number of 
HLA class II 
alleles
Peptide 
length
Other species URL
MHCBN Database with information 
about allele specific MHC 
binding peptides, MHC 
nonbinding, TAP binding, 
TAP nonbinding peptides 
and T-cell epitopes
Database [68, 69] n/s n/s n/s http://crdd.osdd.net/
raghava/mhcbn/index.
html
MHCMIR Predicts binding affinity 
and levels of MHC-II 
peptides from peptide or 
protein sequence
MIR [70] 0 13 All Mouse http://ailab.ist.psu.edu/
mhcmir/predict.html
MHCPRED Predicts binding affinity 
of peptides to MHC class 
I and II molecules and to 
TAP from protein sequence 
and calculates binding 
affinity for heteroclitic 
peptides
Additive 
method, partial 
least square 
regression
[71–73] 11 3 9 Mouse http://www.ddg-
pharmfac.net/mhcpred/
MHCPred/
http://www.ddg-
pharmfac.net/mhcpred/
MHCPred/pepLib.html
MMBPred Predicts mutated high 
affinity and promiscuous 
MHC class-I binding 
peptides from protein 
sequence, epitope 
enhancement, 1–3 AAs 
mutation of nonamer 
peptides
QM [74] 40 inc. 
supertypes
0 9 Rhesus macaque, 
mouse
http://crdd.osdd.net/
raghava/mmbpred/
MULTIPRED Predicts binding of peptides 
to HLA class I and class 
II DR supertypes and 
individual genotypes
Uses 
NetMHCpan 
and 
NetMHCIIpan
[75] 13 
supertypes
13 
supertypes
8–11 for HLA 
class I and 
genotype
9 for HLA 
class II
No http://cvc.dfci.harvard.
edu/multipred2/index.
php
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Name Application Methods Ref. Number of 
HLA class I 
alleles
Number of 
HLA class II 
alleles
Peptide 
length
Other species URL
NetCTL Predicts CTL epitopes 
in protein sequences 
(Cleavage, TAP transport, 
HLA class I binding)
ANN [76] 12 
supertypes
0 9 No http://www.cbs.dtu.dk/
services/NetCTL/
NetMHC Predicts binding of peptide 
to MHC class I molecules 
from peptide or protein 
sequence
ANN [19, 77] 81 (or 12 
supertypes)
0 8–14 Chimpanzee, 
rhesus macaque, 
mouse, cuttle, pig
http://www.cbs.dtu.dk/
services/NetMHC/
NetMHCcons Predicts binding of peptides 
to any known MHC class I 
molecule from peptide or 
protein sequence
Consensus 
(NetMHC, 
NetMHCpan 
and 
PickPocket)
[78] User 
specified
0 8–15 Chimpanzee, 
gorilla, rhesus 
macaque, mouse, 
cuttle, pig
http://www.cbs.dtu.dk/
services/NetMHCcons/
NetMHCII Predicts binding of peptides 
to HLA-DR, HLA-DQ, 
HLA-DP from peptide or 
protein sequence
ANN [79, 80] 0 26 variable Mouse http://www.cbs.dtu.dk/
services/NetMHCII/
NetMHCIIpan Predicts binding of peptides 
to HLA-DR, HLA-DQ, 
HLA-DP from peptide or 
protein sequence
ANN [81, 82] User 
specified
0 Mouse http://www.cbs.dtu.dk/
services/NetMHCIIpan/
NetMHCpan Predicts binding of peptides 
to any known MHC class I 
molecule from peptide or 
protein sequence
ANN [19, 83, 
84]
User 
specified
0 8–14 Chimpanzee, 
gorilla, rhesus 
macaque, mouse, 
cuttle, pig
http://www.cbs.dtu.dk/
services/NetMHCpan/
nHLAPred: 
ANNPred
Predicts MHC Class I 
binding regions in proteins
ANN [85] 26 inc. 
supertypes
0 Mouse http://crdd.osdd.net/
raghava/nhlapred/neural.
html
nHLAPred: 
ComPred
Predicts MHC Class I 
binding regions in proteins
ANN/QM [85] 59 inc. 
supertypes
0 Rhesus macaque, 
mouse
http://crdd.osdd.net/
raghava/nhlapred/comp.
html
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Name Application Methods Ref. Number of 
HLA class I 
alleles
Number of 
HLA class II 
alleles
Peptide 
length
Other species URL
PREDPEP Predicts binding of peptides 
to HLA class I from peptide 
or protein sequence
Published 
coefficient 
tables
[86] 6 0 8–10 
(dependent 
on the allele)
Mouse http://margalit.huji.ac.il/
Teppred/mhc-bind/index.
html
ProPred Predicts MHC Class II 
binding regions in an 
antigen sequence
QM [87] 51 0 No http://crdd.osdd.net/
raghava/propred/
ProPred I Predicts MHC Class I 
binding regions in an 
antigen sequence
QM [88] 39 inc. 
supertypes
0 Mouse, cattle http://crdd.osdd.net/
raghava/propred1/index.
html
Rankpep Predicts binding of peptides 
to MHC class I and class II 
molecules from peptide or 
protein sequence
PSSM [89–91] n/s n/s Dependent 
on the allele
http://imed.med.ucm.es/
Tools/rankpep.html
svmhc Predicts binding of peptides 
to MHC class I molecules 
from peptide or protein 
sequence
SVM, uses 
MHCPEP or 
SYFPEITHI
[92, 93] 31 0 8–10 
(dependent 
on the allele)
No http://svmhc.bioinfo.se/
svmhc//
SYFPEITHI Database of MHC ligands 
and peptide motifs and 
epitope prediction
Matrix/
motif-based, 
published 
motifs
[94] 33 6 8–11 for HLA 
class I; 15 for 
HLA class II
No http://www.syfpeithi.de/
TEPITOPEpan Predicts tissue-specific 
binding of peptides to 
MHC class II molecules 
from peptide or protein 
sequence
PSSM [95] 0 50 9–25 No http://datamining-iip.
fudan.edu.cn/service/
TEPITOPEpan/index.
html
Abbr. HMM = hidden Markov model, SVM = support vector machine, PSSM = position-specific scoring matrix, QM = quantitative matrices, ANN = artificial neuronal 
networks, SMM = stabilized matrix method, MIL = multiple instance learning, MIR = multiple instance regression, n/s = not specified.
Table 1. Listing of peptide prediction tools available on the web [Accessed November 2017].
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Name Underlying database/data source URL for matrices/training data
BIMAS Coefficient tables deduced from the 
published literature by Dr. Kenneth 
Parker, Children’s Hospital Boston
https://www-bimas.cit.nih.gov/cgi-bin/molbio/
hla_coefficient_viewing_page
https://www-bimas.cit.nih.gov/molbio/hla_bind/
hla_references.html
EpiJen AntiJen [96, 97], SYFPEITHI [94] http://www.ddg-pharmfac.net/antijen/AntiJen/
antijenhomepage.htm
hla_a2_smm BIMAS [58], SYFPEITHI [94], data 
described in Peters, Tong [60]
https://zlab.bu.edu/SMM/
IEDB T Cell Epitope 
Prediction Tools
IEDB [61], Sette lab, Buus lab, uses 
diverse predictions methods (see 
webpage)
http://tools.iedb.org/mhci/download/
http://tools.iedb.org/mhcii/download/
Mappp BIMAS [58], SYFPEITHI [94], coefficient 
tables deduced from the literature by 
Kenneth Parker, Children’s Hospital 
Boston
—
MHC2MIL Data by Wang, Sidney [98] —
MHC2PRED JenPep [19], MHCBN [68] —
MHCBN MHCBN [68] —
MHCMIR IEDB [61] —
MHCPRED JenPep [19] —
MMBPred MHCBN [68] —
MULTIPRED See NetMHCpan and NetMHCIIpan —
NetCTL See NetMHC —
NetMHC Trained for 81 HLA alleles including 
HLA-A, -B, -C and –E, n/s
—
NetMHCcons IEDB [61] —
NetMHCII Data by [19] http://www.cbs.dtu.dk/suppl/immunology/
NetMHCII-2.0.php
NetMHCIIpan IEDB [61] http://www.cbs.dtu.dk/suppl/immunology/
NetMHCIIpan-3.0/
NetMHCpan IEDB [61], IMGT/HLA database [1] —
nHLAPred: ANNPred MHCBN [68] —
nHLAPred: ComPred MHCBN [68], BIMAS [58] http://crdd.osdd.net/raghava/nhlapred/matrix.
html
PREDPEP Pairwise potential table by Miyazawa and 
Jernigan [99]
—
ProPred QMs by Sturniolo, Bono [95] http://crdd.osdd.net/raghava/propred/page4.
html
ProPred I BIMAS [58] and matrices by Ruppert, 
Sidney [100] and Sidney, Southwood [101]
http://crdd.osdd.net/raghava/propred1/matrices/
matrix.html
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5. Analysis of naturally presented peptides
The analysis of the individual patient and cell-type-specific immunopeptidome can be real-
ized through sequencing the HLA-bound peptides. It is imperative for all ongoing peptide 
studies and cellular therapies to find peptides that are (1) naturally presented by the distinct 
allele, (2) immunogenic for (at best) a public T-cell repertoire and (3) preferentially presented 
when different peptides are available. A study from Yaciuk et al. showed for example that the 
peptides isolated from HIV-infected T cells differ from predicted peptides and exhibit differ-
ent T-cell reactions, factors that have to be considered in designing immunotherapies [46]. 
That information is only available after immunopeptidome analyses.
In the past, different methods have been applied to answer these questions comprehensively. 
There are two reliable methods to determine peptide sequences from selected HLA alleles. 
First, membrane-bound HLA molecules from recombinant single-antigen-presenting cells [47, 
48] or from donor cells [49, 50] can be captured by affinity chromatographic methods and the 
bound peptides isolated and sequenced by mass spectrometry. Second, the most realizable 
method is the soluble HLA technology [16, 51]. Vectors encoding for soluble forms of HLA 
molecules (Exon 1–4) are transfected or lentivirally transduced into the cell line of choice. An 
optional recombinant tag (e.g., V5 tag) engineered at the C-terminus of the protein enables spe-
cific purification of the recombinant HLA molecule of choice without the challenge of contami-
nation by cellular-self-HLA molecules. Both methods have been compared by Scull et al. [52] 
and indicated as an equivalent for the determination of allele-specific peptides. Furthermore, 
Badrinath et al. [10] could demonstrate that sHLA molecules associate during peptide acquisi-
tion with the loading complex as well. These results prove evidence that the use of sHLA tech-
nology for understanding allele-specific peptide-binding motifs, the prerequisite for updating 
peptide prediction databases, is the most time- and cost-efficient implementation.
For the development of tailor-made T-cell-based immunotherapeutic strategies, the identification 
of tumor-specific HLA ligands is imperative. The production of recombinant sHLA-expressing 
cells derived from various tissues of malignant origins would guide towards understanding 
immune dominance through peptide competition. One of the most innovative applications is 
the peptide fishing from tumor tissue. Immunological tolerance is mediated through T cells that 
Name Underlying database/data source URL for matrices/training data
Rankpep MHCPEP [102], SYFPEITHI [94], 
GenBank [103]
—
svmhc MHCPEP [102], SYFPEITHI [94] http://www.cs.cornell.edu/people/tj/svm_light/
SYFPEITHI Published literature —
TEPITOPEpan n/s http://datamining-iip.fudan.edu.cn/service/
TEPITOPEpan/TEPITOPEpan.html
Abbr. n/s = not specified.
Table 2. Listing of the underlying databases/data sources for peptide binding prediction.
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are primed in the thymus by self-peptides. Therefore, the comprehensive knowledge of the HLA 
immunopeptidome from diseased cells is fundamental for the development of efficient immuno-
therapeutic strategies. The presentation of peptides depends on the health state of a patient. During 
infections, the expression of HLA molecules and thus peptide presentation, including presentation 
of self-peptides, is diminished through an immune escape mechanism of the invasive pathogen.
6. Peptide vaccination
The treatment of cancer represents a great challenge due to the fact that the vast majority of 
HLA-restricted peptides differs from tissue to tissue and is dependent on the tumor entity. 
For that reason, it becomes obvious how fundamentally important the knowledge of the 
tumor-specific peptidome is. For personalized cancer immunotherapies, the knowledge of 
naturally presented peptides [53] represents the exclusive possibility for therapeutical suc-
cess. The analysis of the mutanome, the proteomic content of a diseased cell, includes the dis-
covery of neo-antigens or post-translational-modified peptides and the avoidance of targeting 
self-antigens from healthy tissue. The results of such individual mutanomes might alter dur-
ing the course of tumor progression [16]. In peptide vaccination trials, the use of multiple 
peptides in combination [54, 55] represents a useful method for targeting all MHC-presenting 
cells with the peptide of choice. Yet, since the cell type where the peptide(s) bind to cannot 
be traced, the rates of antitumor immune responses might differ from patient to patient and 
certain tumor cells where, for example, low MHC expression rates might remain undetected 
from the immune system. To achieve a comprehensive and precise analysis of presented 
tumor antigens, the method of antigen discovery and appropriate T-cell assay for knowledge 
of immunogenicity of the dedicated antigen for vaccination is the key factor [56, 57].
7. Conclusion
Peptide selection and presentation is an exquisite biological and immunological event. Every 
single peptide is a mirror of the health state of a distinct cell and determines the outcome of 
immune recognition and responses. For all cellular therapies, the knowledge of the HLA-
subtype specific proteome is crucial for the utilization of ligand prediction tools, which have 
to be implemented where no experimental data are available, yet.
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